Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Blue Sky Pharmaceuticals describes new mu-opioid receptor agonists for pain

Feb. 25, 2020

Novel homeostatic lipid mediators show neuroprotection in rat model of cerebral ischemia

Feb. 25, 2020

FDA approves Vyepti for preventive treatment of migraine

Feb. 24, 2020

Blood vessel caveolae control delivery in the brain

Feb. 24, 2020

PureTech Health and Monash University divulge allopregnanolone prodrugs

Feb. 24, 2020

PD-1 blockade interferes with opioid analgesia

Feb. 24, 2020

Modiodal approved in Japan for idiopathic hypersomnia

Feb. 24, 2020

FDA approves Anjeso for moderate to severe pain

Feb. 21, 2020

Phase IIb/III study of oral masitinib in PPMS and nSPMS meets primary endpoint

Feb. 21, 2020

GeneTX recruits pediatric patients with Angelman syndrome for phase I/II study of GTX-102

Feb. 20, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...